Skip to main content

adg106

adg106: 2 clinical trials tracked.

adg106 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about adg106, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Advanced Solid Tumor
Clinical Trial Registry Records (2)

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Stage I-III HER2 Negative Breast Cancer

NCT05275777Registry updated 2025-07-25·Phase 1/Phase 2
Active, not recruiting

Primary endpoint: Number of participant with treatment related toxicities

Interventionalopen66 targetStarted 2022-05Completion 2030-021 site · SingaporeNational University Hospital, Singapore

A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG116, ADG116 Combined With Toripalimab (Anti-PD-1 Antibody), ADG116 Combined With ADG106 (Anti-CD137 Antibody) in Patients With Advanced/Metastatic Solid Tumors

NCT04501276Registry updated 2026-01-08·Phase 1·ADAG
Completed

Primary endpoint: Number of participants experiencing dose-limiting toxicities escalating dose levels in adults with advanced / metastatic solid tumors

Interventionalopen72 enrolledStarted 2020-09Completion 2025-114 sites · Australia, United StatesAdagene Inc